Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies.
Andrew J. Armstrong
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb
Honoraria - Pfizer
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
James D. Turnbull
No relevant relationships to disclose
Julien Cobert
No relevant relationships to disclose
Tracy Jaffe
Research Funding - Osiris Medical
Michael Roger Harrison
Honoraria - Novartis
Daniel J. George
Consultant or Advisory Role - Bayer; Genentech; Novartis; Pfizer
Honoraria - Genentech; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Exelixis; GlaxoSmithKline; Novartis; Pfizer